Alexion Pharma`s Biologic Strensiq (asfotase alfa) Receives Approval in US
Alexion Pharma`s Biologic Kanuma (sebelipase alfa) Receives Approval in US
Alexion Pharma`s Biologic Soliris (exulizumab) Receives Approval in US
Alexion`s Biologic Ultomiris (ravulizumab-cwvz) Receives Approvals in the US
US FDA approves Amgen`s biosimilar to AZ`s rare blood disorder treatment
AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)
Monte Rosa’s $100M offering: The molecular glue degrader biotech priced the offering at $4.70 per share $GLUE and expects it to close on May 20. At the end of March, it had enough cash and equivalents to take the biotech into the first half of 2026. — Kyle LaHucik
Lights, camera, Alexion! Fresh off an FDA approval for Ultomiris in NMOSD, AstraZeneca’s rare disease unit has put out a film sharing patient stories.
AstraZeneca’s rare disease arm Alexion is debuting an original short film Thursday for patients with the rare neurological condition neuromyelitis optica spectrum disorder (NMOSD).
LOUISVILLE, Ky., April 08, 2024 (GLOBE NEWSWIRE) -- Onco360®, the nation's leading independent Specialty Pharmacy, has been selected as a national pharmacy partner by Alexion Pharmaceuticals for...